Skip to main content

Advertisement

SpringerLink
Log in

Reprogramming of mitochondrial proline metabolism promotes liver tumorigenesis

  • Minireview Article
  • Published:
Amino Acids Aims and scope Submit manuscript

Abstract

Dysregulated cellular energetics has recently been recognized as a hallmark of cancer and garnered attention as a potential targeting strategy for cancer therapeutics. Cancer cells reprogram metabolic activities to meet bio-energetic, biosynthetic and redox requirements needed to sustain indefinite proliferation. In many cases, metabolic reprogramming is the result of complex interactions between genetic alterations in well-known oncogenes and tumor suppressors and epigenetic changes. While the metabolism of the two most abundant nutrients, glucose and glutamine, is reprogrammed in a wide range of cancers, accumulating evidence demonstrates that additional metabolic pathways are also critical for cell survival and growth. Proline metabolism is one such metabolic pathway that promotes tumorigenesis in multiple cancer types, including liver cancer, which is the fourth main cause of cancer mortality in the world. Despite the recent spate of approved treatments, including targeted therapy and combined immunotherapies, there has been no significant gain in clinical benefits in the majority of liver cancer patients. Thus, exploring novel therapeutic strategies and identifying new molecular targets remains a top priority for liver cancer. Two of the enzymes in the proline biosynthetic pathway, pyrroline-5-carboxylate reductase (PYCR1) and Aldehyde Dehydrogenase 18 Family Member A1 (ALDH18A1), are upregulated in liver cancer of both human and animal models, while proline catabolic enzymes, such as proline dehydrogenase (PRODH) are downregulated. Here we review the latest evidence linking proline metabolism to liver and other cancers and potential mechanisms of action for the proline pathway in cancer development.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  • Adams E, Frank L (1980) Metabolism of proline and the hydroxyprolines. Annu Rev Biochem 49:1005–1061

    Article  CAS  PubMed  Google Scholar 

  • Boroughs LK, DeBerardinis RJ (2015) Metabolic pathways promoting cancer cell survival and growth. Nat Cell Biol 17:351–359

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424

    Article  PubMed  Google Scholar 

  • Bruck R, Shirin H, Aeed H, Matas Z, Hochman A, Pines M, Avni Y (2001) Prevention of hepatic cirrhosis in rats by hydroxyl radical scavengers. J Hepatol 35:457–464

    Article  CAS  PubMed  Google Scholar 

  • Burke L, Guterman I, Palacios Gallego R, Britton RG, Burschowsky D, Tufarelli C, Rufini A (2020) The Janus-like role of proline metabolism in cancer. Cell Death Discov 6:104

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Cai F, Miao Y, Liu C, Wu T, Shen S, Su X, Shi Y (2018) Pyrroline-5-carboxylate reductase 1 promotes proliferation and inhibits apoptosis in non-small cell lung cancer. Oncol Lett 15:731–740

    PubMed  Google Scholar 

  • Cantor JR, Sabatini DM (2012) Cancer cell metabolism: one hallmark, many faces. Cancer Discov 2:881–898

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Chen Y, Huang Y, Reiberger T, Duyverman AM, Huang P, Samuel R, Hiddingh L, Roberge S, Koppel C, Lauwers GY et al (2014) Differential effects of sorafenib on liver versus tumor fibrosis mediated by stromal-derived factor 1 alpha/C-X-C receptor type 4 axis and myeloid differentiation antigen-positive myeloid cell infiltration in mice. Hepatology 59:1435–1447

    Article  CAS  PubMed  Google Scholar 

  • Chen S, Yang X, Yu M, Wang Z, Liu B, Liu M, Liu L, Ren M, Qi H, Zou J et al (2019) SIRT3 regulates cancer cell proliferation through deacetylation of PYCR1 in proline metabolism. Neoplasia 21:665–675

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Christensen EM, Patel SM, Korasick DA, Campbell AC, Krause KL, Becker DF, Tanner JJ (2017) Resolving the cofactor-binding site in the proline biosynthetic enzyme human pyrroline-5-carboxylate reductase 1. J Biol Chem 292:7233–7243

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Christensen EM, Bogner AN, Vandekeere A, Tam GS, Patel SM, Becker DF, Fendt S-M, Tanner JJ (2020) In crystallo screening for proline analog inhibitors of the proline cycle enzyme PYCR1. J Biol Chemistry 295(52):18316-18327

    Article  CAS  Google Scholar 

  • Ciccarese F, Ciminale V (2017) Escaping death: mitochondrial redox homeostasis in cancer cells. Front Oncol 7:117

    Article  PubMed  PubMed Central  Google Scholar 

  • D’Aniello C, Cermola F, Palamidessi A, Wanderlingh LG, Gagliardi M, Migliaccio A, Varrone F, Casalino L, Matarazzo MR, De Cesare D et al (2019) Collagen prolyl hydroxylation-dependent metabolic perturbation governs epigenetic remodeling and mesenchymal transition in pluripotent and cancer cells. Cancer Res 79:3235–3250

    Article  CAS  PubMed  Google Scholar 

  • D’Aniello C, Patriarca EJ, Phang JM, Minchiotti G (2020) Proline metabolism in tumor growth and metastatic progression. Front Oncol 10:776

    Article  PubMed  PubMed Central  Google Scholar 

  • De Ingeniis J, Ratnikov B, Richardson AD, Scott DA, Aza-Blanc P, De SK, Kazanov M, Pellecchia M, Ronai Z, Osterman AL, Smith JW (2012) Functional specialization in proline biosynthesis of melanoma. PLoS ONE 7:e45190

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • De Matteis S, Ragusa A, Marisi G, De Domenico S, Casadei Gardini A, Bonafe M, Giudetti AM (2018) Aberrant metabolism in hepatocellular carcinoma provides diagnostic and therapeutic opportunities. Oxid Med Cell Longev 2018:7512159

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • de Jonge MJ, Dumez H, Verweij J, Yarkoni S, Snyder D, Lacombe D, Marreaud S, Yamaguchi T, Punt CJ, van Oosterom A (2006) Phase I and pharmacokinetic study of halofuginone, an oral quinazolinone derivative in patients with advanced solid tumours. Eur J Cancer 42:1768–1774

    Article  PubMed  CAS  Google Scholar 

  • Debacker AJ, Voutila J, Catley M, Blakey D, Habib N (2020) Delivery of oligonucleotides to the liver with GalNAc: from research to registered therapeutic drug. Mol Ther 28:1759–1771

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • DeBerardinis RJ, Chandel NS (2016) Fundamentals of cancer metabolism. Sci Adv 2:e1600200

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB (2008) The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab 7:11–20

    Article  CAS  PubMed  Google Scholar 

  • Ding J, Kuo ML, Su L, Xue L, Luh F, Zhang H, Wang J, Lin TG, Zhang K, Chu P et al (2017) Human mitochondrial pyrroline-5-carboxylate reductase 1 promotes invasiveness and impacts survival in breast cancers. Carcinogenesis 38:519–531

    Article  CAS  PubMed  Google Scholar 

  • Ding Z, Ericksen RE, Escande-Beillard N, Lee QY, Loh A, Denil S, Steckel M, Haegebarth A, Wai Ho TS, Chow P et al (2020) Metabolic pathway analyses identify proline biosynthesis pathway as a promoter of liver tumorigenesis. J Hepatol 72:725–735

    Article  CAS  PubMed  Google Scholar 

  • Donald SP, Sun XY, Hu CA, Yu J, Mei JM, Valle D, Phang JM (2001) Proline oxidase, encoded by p53-induced gene-6, catalyzes the generation of proline-dependent reactive oxygen species. Cancer Res 61:1810–1815

    CAS  PubMed  Google Scholar 

  • Elia I, Broekaert D, Christen S, Boon R, Radaelli E, Orth MF, Verfaillie C, Grunewald TGP, Fendt SM (2017) Proline metabolism supports metastasis formation and could be inhibited to selectively target metastasizing cancer cells. Nat Commun 8:15267

    Article  PubMed  PubMed Central  Google Scholar 

  • El-Serag HB (2011) Hepatocellular carcinoma. N Engl J Med 365:1118–1127

    Article  CAS  PubMed  Google Scholar 

  • Ericksen RE, Lim SL, McDonnell E, Shuen WH, Vadiveloo M, White PJ, Ding Z, Kwok R, Lee P, Radda GK et al (2019) Loss of BCAA catabolism during carcinogenesis enhances mTORC1 activity and promotes tumor development and progression. Cell Metab 29(1151–1165):e1156

    Google Scholar 

  • Faubert B, Solmonson A, DeBerardinis RJ (2020) Metabolic reprogramming and cancer progression. Science 368:aaw5473

    Article  CAS  Google Scholar 

  • Feng GX, Li J, Yang Z, Zhang SQ, Liu YX, Zhang WY, Ye LH, Zhang XD (2017) Hepatitis B virus X protein promotes the development of liver fibrosis and hepatoma through downregulation of miR-30e targeting P4HA2 mRNA. Oncogene 36:6895–6905

    Article  CAS  PubMed  Google Scholar 

  • Fichman Y, Gerdes SY, Kovacs H, Szabados L, Zilberstein A, Csonka LN (2015) Evolution of proline biosynthesis: enzymology, bioinformatics, genetics, and transcriptional regulation. Biol Rev Camb Philos Soc 90:1065–1099

    Article  PubMed  Google Scholar 

  • Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, Kudo M, Breder V, Merle P, Kaseb AO et al (2020a) Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med 382:1894–1905

    Article  CAS  PubMed  Google Scholar 

  • Finn RS, Ryoo BY, Merle P, Kudo M, Bouattour M, Lim HY, Breder V, Edeline J, Chao Y, Ogasawara S et al (2020b) Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial. J Clin Oncol 38:193–202

    Article  CAS  PubMed  Google Scholar 

  • Fung MKL, Chan GC (2017) Drug-induced amino acid deprivation as strategy for cancer therapy. J Hematol Oncol 10:144

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Gao X, Sanderson SM, Dai Z, Reid MA, Cooper DE, Lu M, Richie JP Jr, Ciccarella A, Calcagnotto A, Mikhael PG et al (2019) Dietary methionine influences therapy in mouse cancer models and alters human metabolism. Nature 572:397–401

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Gaude E, Frezza C (2016) Tissue-specific and convergent metabolic transformation of cancer correlates with metastatic potential and patient survival. Nat Commun 7:13041

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Guo L, Cui C, Zhang K, Wang J, Wang Y, Lu Y, Chen K, Yuan J, Xiao G, Tang B et al (2019) Kindlin-2 links mechano-environment to proline synthesis and tumor growth. Nat Commun 10:845

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Guo L, Cui C, Wang J, Yuan J, Yang Q, Zhang P, Su W, Bao R, Ran J, Wu C (2020) PINCH-1 regulates mitochondrial dynamics to promote proline synthesis and tumor growth. Nat Commun 11:4913

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646–674

    Article  CAS  PubMed  Google Scholar 

  • Henke E, Nandigama R, Ergun S (2019) Extracellular matrix in the tumor microenvironment and its impact on cancer therapy. Front Mol Biosci 6:160

    Article  CAS  PubMed  Google Scholar 

  • Hollinshead KER, Munford H, Eales KL, Bardella C, Li C, Escribano-Gonzalez C, Thakker A, Nonnenmacher Y, Kluckova K, Jeeves M et al (2018) Oncogenic IDH1 mutations promote enhanced proline synthesis through PYCR1 to support the maintenance of mitochondrial redox homeostasis. Cell Rep 22:3107–3114

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hu J, Locasale JW, Bielas JH, O’Sullivan J, Sheahan K, Cantley LC, Vander Heiden MG, Vitkup D (2013) Heterogeneity of tumor-induced gene expression changes in the human metabolic network. Nat Biotechnol 31:522–529

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Huo S, Yu H, Li C, Zhang J, Liu T (2015) Effect of halofuginone on the inhibition of proliferation and invasion of hepatocellular carcinoma HepG2 cell line. Int J Clin Exp Pathol 8:15863–15870

    CAS  PubMed  PubMed Central  Google Scholar 

  • Jemal A, Ward EM, Johnson CJ, Cronin KA, Ma J, Ryerson B, Mariotto A, Lake AJ, Wilson R, Sherman RL et al (2017) Annual report to the nation on the status of cancer, 1975–2014 featuring survival. J Natl Cancer Inst 109:djx30

    Article  Google Scholar 

  • Jin H, Wang S, Zaal EA, Wang C, Wu H, Bosma A, Jochems F, Isima N, Jin G, Lieftink C et al (2020) A powerful drug combination strategy targeting glutamine addiction for the treatment of human liver cancer. Elife 9:e56749

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kardos GR, Wastyk HC, Robertson GP (2015) Disruption of proline synthesis in melanoma inhibits protein production mediated by the GCN2 pathway. Mol Cancer Res 13:1408–1420

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Keller TL, Zocco D, Sundrud MS, Hendrick M, Edenius M, Yum J, Kim YJ, Lee HK, Cortese JF, Wirth DF et al (2012) Halofuginone and other febrifugine derivatives inhibit prolyl-tRNA synthetase. Nat Chem Biol 8:311–317

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kowalik MA, Columbano A, Perra A (2017) Emerging role of the pentose phosphate pathway in hepatocellular carcinoma. Front Oncol 7:87

    Article  PubMed  PubMed Central  Google Scholar 

  • Krishnan N, Dickman MB, Becker DF (2008) Proline modulates the intracellular redox environment and protects mammalian cells against oxidative stress. Free Radic Biol Med 44:671–681

    Article  CAS  PubMed  Google Scholar 

  • Kuo ML, Lee MB, Tang M, den Besten W, Hu S, Sweredoski MJ, Hess S, Chou CM, Changou CA, Su M et al (2016) PYCR1 and PYCR2 interact and collaborate with RRM2B to protect cells from overt oxidative stress. Sci Rep 6:18846

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kuo CL, Chou HY, Chiu YC, Cheng AN, Fan CC, Chang YN, Chen CH, Jiang SS, Chen NJ, Lee AY (2020) Mitochondrial oxidative stress by Lon-PYCR1 maintains an immunosuppressive tumor microenvironment that promotes cancer progression and metastasis. Cancer Lett 474:138–150

    Article  CAS  PubMed  Google Scholar 

  • Lee JI, Campbell JS (2014) Role of desmoplasia in cholangiocarcinoma and hepatocellular carcinoma. J Hepatol 61:432–434

    Article  PubMed  Google Scholar 

  • Leone RD, Zhao L, Englert JM, Sun IM, Oh MH, Sun IH, Arwood ML, Bettencourt IA, Patel CH, Wen J et al (2019) Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion. Science 366:1013–1021

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Li F, Huangyang P, Burrows M, Guo K, Riscal R, Godfrey J, Lee KE, Lin N, Lee P, Blair IA et al (2020) FBP1 loss disrupts liver metabolism and promotes tumorigenesis through a hepatic stellate cell senescence secretome. Nat Cell Biol 22:728–739

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Lieu EL, Nguyen T, Rhyne S, Kim J (2020) Amino acids in cancer. Exp Mol Med 52:15–30

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Liu Y, Borchert GL, Donald SP, Surazynski A, Hu CA, Weydert CJ, Oberley LW, Phang JM (2005) MnSOD inhibits proline oxidase-induced apoptosis in colorectal cancer cells. Carcinogenesis 26:1335–1342

    Article  CAS  PubMed  Google Scholar 

  • Liu Y, Borchert GL, Donald SP, Diwan BA, Anver M, Phang JM (2009) Proline oxidase functions as a mitochondrial tumor suppressor in human cancers. Cancer Res 69:6414–6422

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Liu W, Glunde K, Bhujwalla ZM, Raman V, Sharma A, Phang JM (2012a) Proline oxidase promotes tumor cell survival in hypoxic tumor microenvironments. Cancer Res 72:3677–3686

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Liu W, Le A, Hancock C, Lane AN, Dang CV, Fan TW, Phang JM (2012b) Reprogramming of proline and glutamine metabolism contributes to the proliferative and metabolic responses regulated by oncogenic transcription factor c-MYC. Proc Natl Acad Sci U S A 109:8983–8988

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Liu W, Hancock CN, Fischer JW, Harman M, Phang JM (2015) Proline biosynthesis augments tumor cell growth and aerobic glycolysis: involvement of pyridine nucleotides. Sci Rep 5:17206

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Liu Y, Mao C, Wang M, Liu N, Ouyang L, Liu S, Tang H, Cao Y, Wang X, Xiao D et al (2020b) Cancer progression is mediated by proline catabolism in non-small cell lung cancer. Oncogene 39:2358–2376

    Article  CAS  PubMed  Google Scholar 

  • Liu M, Wang Y, Yang C, Ruan Y, Bai C, Chu Q, Cui Y, Chen C, Ying G, Li B (2020a) Inhibiting both proline biosynthesis and lipogenesis synergistically suppresses tumor growth. J Exp Med 217:e20191226

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Loayza-Puch F, Rooijers K, Buil LC, Zijlstra J, Oude Vrielink JF, Lopes R, Ugalde AP, van Breugel P, Hofland I, Wesseling J et al (2016) Tumour-specific proline vulnerability uncovered by differential ribosome codon reading. Nature 530:490–494

    Article  CAS  PubMed  Google Scholar 

  • Luengo A, Gui DY, Vander Heiden MG (2017) Targeting metabolism for cancer therapy. Cell Chem Biol 24:1161–1180

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Maddocks ODK, Athineos D, Cheung EC, Lee P, Zhang T, van den Broek NJF, Mackay GM, Labuschagne CF, Gay D, Kruiswijk F et al (2017) Modulating the therapeutic response of tumours to dietary serine and glycine starvation. Nature 544:372–376

    Article  CAS  PubMed  Google Scholar 

  • Milne K, Sun J, Zaal EA, Mowat J, Celie PHN, Fish A, Berkers CR, Forlani G, Loayza-Puch F, Jamieson C, Agami R (2019) A fragment-like approach to PYCR1 inhibition. Bioorg Med Chem Lett 29:2626–2631

    Article  CAS  PubMed  Google Scholar 

  • Mossenta M, Busato D, Dal Bo M, Toffoli G (2020) Glucose metabolism and oxidative stress in hepatocellular carcinoma: role and possible implications in novel therapeutic strategies. Cancers (Basel) 12:1668

    Article  CAS  Google Scholar 

  • Nagler A, Ohana M, Shibolet O, Shapira MY, Alper R, Vlodavsky I, Pines M, Ilan Y (2004) Suppression of hepatocellular carcinoma growth in mice by the alkaloid coccidiostat halofuginone. Eur J Cancer 40:1397–1403

    Article  CAS  PubMed  Google Scholar 

  • Natarajan SK, Zhu W, Liang X, Zhang L, Demers AJ, Zimmerman MC, Simpson MA, Becker DF (2012) Proline dehydrogenase is essential for proline protection against hydrogen peroxide-induced cell death. Free Radic Biol Med 53:1181–1191

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Nikam RR, Gore KR (2018) Journey of siRNA: clinical developments and targeted delivery. Nucleic Acid Ther 28:209–224

    Article  CAS  PubMed  Google Scholar 

  • Nilsson R, Jain M, Madhusudhan N, Sheppard NG, Strittmatter L, Kampf C, Huang J, Asplund A, Mootha VK (2014) Metabolic enzyme expression highlights a key role for MTHFD2 and the mitochondrial folate pathway in cancer. Nat Commun 5:3128

    Article  PubMed  CAS  Google Scholar 

  • Pandhare J, Donald SP, Cooper SK, Phang JM (2009) Regulation and function of proline oxidase under nutrient stress. J Cell Biochem 107:759–768

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Patra KC, Hay N (2014) The pentose phosphate pathway and cancer. Trends Biochem Sci 39:347–354

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Pavlova NN, Thompson CB (2016) The emerging hallmarks of cancer metabolism. Cell Metab 23:27–47

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Phang JM (1985) The regulatory functions of proline and pyrroline-5-carboxylic acid. Curr Top Cell Regul 25:91–132

    Article  CAS  PubMed  Google Scholar 

  • Phang JM (2019) Proline metabolism in cell regulation and cancer biology: recent advances and hypotheses. Antioxid Redox Signal 30:635–649

    Article  CAS  PubMed  Google Scholar 

  • Phang JM, Liu W, Zabirnyk O (2010) Proline metabolism and microenvironmental stress. Annu Rev Nutr 30:441–463

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Phang JM, Liu W, Hancock C, Christian KJ (2012) The proline regulatory axis and cancer. Front Oncol 2:60

    Article  PubMed  PubMed Central  Google Scholar 

  • Phang JM, Liu W, Hancock CN, Fischer JW (2015) Proline metabolism and cancer: emerging links to glutamine and collagen. Curr Opin Clin Nutr Metab Care 18:71–77

    Article  CAS  PubMed  Google Scholar 

  • Polyak K, Xia Y, Zweier JL, Kinzler KW, Vogelstein B (1997) A model for p53-induced apoptosis. Nature 389:300–305

    Article  CAS  PubMed  Google Scholar 

  • Possemato R, Marks KM, Shaul YD, Pacold ME, Kim D, Birsoy K, Sethumadhavan S, Woo HK, Jang HG, Jha AK et al (2011) Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature 476:346–350

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Provenzano PP, Inman DR, Eliceiri KW, Knittel JG, Yan L, Rueden CT, White JG, Keely PJ (2008) Collagen density promotes mammary tumor initiation and progression. BMC Med 6:11

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Ray KK, Wright RS, Kallend D, Koenig W, Leiter LA, Raal FJ, Bisch JA, Richardson T, Jaros M, Wijngaard PLJ, Kastelein JJP (2020) Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. N Engl J Med 382:1507–1519

    Article  CAS  PubMed  Google Scholar 

  • Sahu N, Dela Cruz D, Gao M, Sandoval W, Haverty PM, Liu J, Stephan JP, Haley B, Classon M, Hatzivassiliou G, Settleman J (2016) Proline starvation induces unresolved ER stress and hinders mTORC1-dependent tumorigenesis. Cell Metab 24:753–761

    Article  CAS  PubMed  Google Scholar 

  • Scott GK, Yau C, Becker BC, Khateeb S, Mahoney S, Jensen MB, Hann B, Cowen BJ, Pegan SD, Benz CC (2019) Targeting mitochondrial proline dehydrogenase with a suicide inhibitor to exploit synthetic lethal interactions with p53 upregulation and glutaminase inhibition. Mol Cancer Ther 18:1374–1385

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Song M, Kim SH, Im CY, Hwang HJ (2018) Recent development of small molecule glutaminase inhibitors. Curr Top Med Chem 18:432–443

    Article  CAS  PubMed  Google Scholar 

  • Spira G, Mawasi N, Paizi M, Anbinder N, Genina O, Alexiev R, Pines M (2002) Halofuginone, a collagen type I inhibitor improves liver regeneration in cirrhotic rats. J Hepatol 37:331–339

    Article  CAS  PubMed  Google Scholar 

  • Struys EA, Jansen EE, Salomons GS (2014) Human pyrroline-5-carboxylate reductase (PYCR1) acts on Delta(1)-piperideine-6-carboxylate generating l-pipecolic acid. J Inherit Metab Dis 37:327–332

    Article  CAS  PubMed  Google Scholar 

  • Szabados L, Savoure A (2010) Proline: a multifunctional amino acid. Trends Plant Sci 15:89–97

    Article  CAS  PubMed  Google Scholar 

  • Tanner JJ, Fendt SM, Becker DF (2018) The proline cycle as a potential cancer therapy target. Biochemistry 57:3433–3444

    Article  CAS  PubMed  Google Scholar 

  • Villanueva A (2019) Hepatocellular carcinoma. N Engl J Med 380:1450–1462

    Article  CAS  PubMed  Google Scholar 

  • Wang T, Fu X, Jin T, Zhang L, Liu B, Wu Y, Xu F, Wang X, Ye K, Zhang W, Ye L (2019) Aspirin targets P4HA2 through inhibiting NF-kappaB and LMCD1-AS1/let-7g to inhibit tumour growth and collagen deposition in hepatocellular carcinoma. EBioMedicine 45:168–180

    Article  PubMed  PubMed Central  Google Scholar 

  • Ward PS, Thompson CB (2012) Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell 21:297–308

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Weijin F, Zhibin X, Shengfeng Z, Xiaoli Y, Qijian D, Jiayi L, Qiumei L, Yilong C, Hua M, Deyun L, Jiwen C (2019) The clinical significance of PYCR1 expression in renal cell carcinoma. Medicine (Baltimore) 98:e16384

    Article  CAS  Google Scholar 

  • Winkler J, Abisoye-Ogunniyan A, Metcalf KJ, Werb Z (2020) Concepts of extracellular matrix remodelling in tumour progression and metastasis. Nat Commun 11:5120

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Wise DR, Thompson CB (2010) Glutamine addiction: a new therapeutic target in cancer. Trends Biochem Sci 35:427–433

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Wu Z, Wei D, Gao W, Xu Y, Hu Z, Ma Z, Gao C, Zhu X, Li Q (2015) TPO-induced metabolic reprogramming drives liver metastasis of colorectal cancer CD110+ tumor-initiating cells. Cell Stem Cell 17:47–59

    Article  CAS  PubMed  Google Scholar 

  • Xia W, Zhuang J, Wang G, Ni J, Wang J, Ye Y (2017) P4HB promotes HCC tumorigenesis through downregulation of GRP78 and subsequent upregulation of epithelial-to-mesenchymal transition. Oncotarget 8:8512–8521

    Article  PubMed  Google Scholar 

  • Xiao S, Li S, Yuan Z, Zhou L (2020) Pyrroline-5-carboxylate reductase 1 (PYCR1) upregulation contributes to gastric cancer progression and indicates poor survival outcome. Ann Transl Med 8:937

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Yang L, Venneti S, Nagrath D (2017) Glutaminolysis: a hallmark of cancer metabolism. Annu Rev Biomed Eng 19:163–194

    Article  CAS  PubMed  Google Scholar 

  • Yoo HC, Park SJ, Nam M, Kang J, Kim K, Yeo JH, Kim JK, Heo Y, Lee HS, Lee MY et al (2020) A variant of SLC1A5 is a mitochondrial glutamine transporter for metabolic reprogramming in cancer cells. Cell Metab 31(267–283):e212

    Google Scholar 

  • Zarrinpar A (2017) Metabolic pathway inhibition in liver cancer. SLAS Technol 22:237–244

    Article  PubMed  Google Scholar 

  • Zeng T, Zhu L, Liao M, Zhuo W, Yang S, Wu W, Wang D (2017) Knockdown of PYCR1 inhibits cell proliferation and colony formation via cell cycle arrest and apoptosis in prostate cancer. Med Oncol 34:27

    Article  PubMed  CAS  Google Scholar 

  • Zhang L, Becker DF (2015) Connecting proline metabolism and signaling pathways in plant senescence. Front Plant Sci 6:552

    PubMed  PubMed Central  Google Scholar 

  • Zhang M, White TA, Schuermann JP, Baban BA, Becker DF, Tanner JJ (2004) Structures of the Escherichia coli PutA proline dehydrogenase domain in complex with competitive inhibitors. Biochemistry 43:12539–12548

    Article  CAS  PubMed  Google Scholar 

  • Zhang J, Pavlova NN, Thompson CB (2017) Cancer cell metabolism: the essential role of the nonessential amino acid, glutamine. EMBO J 36:1302–1315

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Zhou H, Sun L, Yang XL, Schimmel P (2013) ATP-directed capture of bioactive herbal-based medicine on human tRNA synthetase. Nature 494:121–124

    Article  CAS  PubMed  Google Scholar 

  • Zhuang J, Song Y, Ye Y, He S, Ma X, Zhang M, Ni J, Wang J, Xia W (2019) PYCR1 interference inhibits cell growth and survival via c-Jun N-terminal kinase/insulin receptor substrate 1 (JNK/IRS1) pathway in hepatocellular cancer. J Transl Med 17:343

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Funding

This study was funded by A*STAR Biomedical Research Council.

Author information

Authors and Affiliations

  1. Institute of Molecular and Cell Biology, Agency for Science, Technology and Research (A*STAR), #02-02 Helios, 11 Biopolis Way, Singapore, 138667, Singapore

    Zhaobing Ding, Russell E. Ericksen, Qian Yi Lee & Weiping Han

Authors
  1. Zhaobing Ding
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Russell E. Ericksen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Qian Yi Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Weiping Han
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

ZD, RE, QL wrote the manuscript. WH commented and edited the manuscript.

Corresponding author

Correspondence to Weiping Han.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Research involving human participants and/or animals

This is a review article and does not involve any human participants or animal work.

Informed consent

The article is a review article, there are no human participants involved.

Additional information

Handling Editor J. M. Phang.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ding, Z., Ericksen, R.E., Lee, Q.Y. et al. Reprogramming of mitochondrial proline metabolism promotes liver tumorigenesis. Amino Acids 53, 1807–1815 (2021). https://doi.org/10.1007/s00726-021-02961-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00726-021-02961-5

Keywords

Search

Navigation